OPK - オプコ・ヘルス （Opko Health Inc.） オプコ・ヘルスOPKのチャート
OPKの企業情報
| symbol | OPK |
|---|---|
| 会社名 | Opko Health Inc （オプコ・ヘルス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | 医薬品 医療関連（Health Care） |
| 概要 | 事業概要 OPKO Health Inc. is a healthcare company. Its segments include Pharmaceutical Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile Mexico Ireland Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations. Through Bio-Reference it operates laboratory divisions such as Bio-Reference GenPath (Oncology) GenPath (Women's Health) GeneDx and Laboratorio Bueno Salud. As of December 31 2016 it had one commercial stage pharmaceutical product and several pharmaceutical compounds and technologies in various stages of research and development for a range of indications and conditions including Renal Products Biologics hGH-CTP Factor VII Oxyntomodulin active pharmaceutical ingredients Oligonucleotide Therapeutics NK-1 Program Asthma and chronic obstructive pulmonary disease. オプコ・ヘルスは、米国のバイオ医薬品および診断法開発会社。ポイントオブケア検査、デベロップメントテスト、分子診断テスト、および独自の医薬品やワクチンなどによる診断、治療、予防法を開発。また、前立腺癌の検査薬を開発するほか、二次副甲状腺機能亢進症を治療するためのビタミンDプロホルモンなど研究開発のための医薬化合物を手掛ける。 Opko Health Inc. is a multinational biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large, rapidly growing markets by leveraging its discovery, development, and commercialization expertise and novel and proprietary technologies. |
| 本社所在地 | 4400 Biscayne Blvd. Miami FL 33137 USA |
| 代表者氏名 | Phillip Frost フィリップフロスト |
| 代表者役職名 | Chairman of the Board Chief Executive Officer 取締役会長兼最高経営責任者 |
| 電話番号 | +1 305-575-4138 |
| 設立年月日 | 33512 |
| 市場名 | NYSE（ニューヨーク証券取引所） |
| ipoyear | ―年 |
| 従業員数 | 5936人 |
| url | www.opko.com |
| nasdaq_url | https://www.nasdaq.com/symbol/opk |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -151.44300 |
| 終値（lastsale） | 3.68 |
| 時価総額（marketcap） | 2059957261.6 |
| 時価総額 | 時価総額（百万ドル） 29.578 |
| 売上高 | 売上高（百万ドル） 975.79400 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 2138.946 |
| 当期純利益 | 当期純利益（百万ドル） -309.66200 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Opko Health Inc. revenues decreased 7% to $518.6M. Net loss decreased 4% to $49.3M. Revenues reflect Diagnostics segment decrease of 12% to $427.4M Pharmaceutical segment decrease of 29% to $56.4M United States segment decrease of 16% to $437.8M Israel segment decrease of 48% to $6.1M Ireland segment decrease of 11% to $38.1M. Lower net loss reflects Pharmaceutical segment loss decrease of 40% to $20.8M. |
OPKのテクニカル分析
OPKのニュース
OPKO Health Inc. (NASDAQ: OPK) Is Down -10.40% Year-To-Date, But There Is Speculation That It Will Rally 2023/03/07 13:30:00 Stocks Register
OPKO Health Inc. (NASDAQ:OPK) traded at $1.12 at close of the session on Monday, 03/06/23, made a downward move of -3.45% on its previous day’s price. Looking at the stock we see that its previous close was $1.16 and the beta (5Y monthly) reads 1.68 with the day’s price range being $1.11 – $1.17. In … OPKO Health Inc. (NASDAQ: OPK) Is Down -10.40% Year-To-Date, But There Is Speculation That It Will Rally Read More »
Few Options Left For OPKO Health To Heal 2023/03/01 10:14:45 Seeking Alpha
OPKO Health''s losses continue to mount, and revenue falls from diagnostics paint an unhealthy investment picture for retail value investors. Read why OPK stock is a Hold.
OPKO Health Inc. (NASDAQ:OPK) stock: Is this a flash in the pan today? 2023/02/27 20:00:00 US Post News
Currently, OPKO Health Inc.’s (OPK) stock is trading at $1.12, marking a gain of 6.13% from last night’s close. At this price, the stock is -70.24% below its 52-week high of $3.78 and 12.50% above its 52-week low of $1.00. Based on the past 30-day period, the stock price is -23.84% below the high and […]
Current Stocks in the Spotlight: OPKO Health, Inc. (NASDAQ:OPK), Cybin Inc. (AMEX:CYBN) 2023/02/24 17:57:24 Stock Equity
OPK has seen its SMA50 which is now -20.03%. In looking the SMA 200 we see that the stock has seen a -49.02%. CYBN has seen its SMA50 which is … The post Current Stocks in the Spotlight: OPKO Health, Inc. (NASDAQ:OPK), Cybin Inc. (AMEX:CYBN) appeared first on Stocks Equity .
Opko Health (OPK) Q4 2022 Earnings Call Transcript 2023/02/24 06:00:43 The Motley Fool
OPK earnings call for the period ending December 31, 2022.
Opko Health – Consensus Indicates Potential 94.4% Upside 2022/04/01 12:20:59 DirectorsTalk
Opko Health with ticker code (OPK) now have 4 analysts covering the stock with the consensus suggesting a rating of ''Buy''. The range between the high target price and low target price is between 8.5 and 5.5 calculating the average target price we see 6.88. Now with the previous closing price of 3.54 this would indicate that there is a potential upside of 94.4%. There is a 50 day moving average of 3.28 and the 200 day moving average is 3.77. The market capitalisation for the company is $2,344m. Company Website: https://www.opko.com [stock_market_widget type="chart" template="basic" color="green" assets="OPK" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $4,556m based on the market concensus. OPKO Health, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company''s Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women''s health, and correctional healthcare to physician offices, clinics, hospitals, employers and governmental units; and a novel diagnostic instrument system to provide blood test results in the point-of-care setting, as well as 4Kscore prostate cancer testing services.
OPKO Health CEO raises his take at the company further (NASDAQ:OPK) 2022/03/15 16:43:36 Seeking Alpha
COVID-19 test maker, OPKO Health <> is trading higher on Tuesday after Chief Executive and Chairman, Dr
OPKO Health''s unit, Saol Therapeutics team up to detect patients with rare disease 2022/03/01 11:27:03 Seeking Alpha
Saol Therapeutics is collaborating with OPKO Health''s (OPK) unit GeneDx to help in identifying patients diagnosed with a rare mitochondrial disease, Pyruvate Dehydrogenase…
Opko Health – Consensus Indicates Potential 94.4% Upside 2022/04/01 12:20:59 DirectorsTalk
Opko Health with ticker code (OPK) now have 4 analysts covering the stock with the consensus suggesting a rating of ''Buy''. The range between the high target price and low target price is between 8.5 and 5.5 calculating the average target price we see 6.88. Now with the previous closing price of 3.54 this would indicate that there is a potential upside of 94.4%. There is a 50 day moving average of 3.28 and the 200 day moving average is 3.77. The market capitalisation for the company is $2,344m. Company Website: https://www.opko.com [stock_market_widget type="chart" template="basic" color="green" assets="OPK" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $4,556m based on the market concensus. OPKO Health, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company''s Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women''s health, and correctional healthcare to physician offices, clinics, hospitals, employers and governmental units; and a novel diagnostic instrument system to provide blood test results in the point-of-care setting, as well as 4Kscore prostate cancer testing services.